AGEN AGEN

Agenus Stock Price

2.81
-0.19 (-6.33%)
Upgrade to Real-Time
Afterhours (Closed)
2.81
Volume 2,461,283
Bid Price 2.81
Ask Price 2.92
News -
Day High 2.97

Low
1.25

52 Week Range

High
3.62

Day Low 2.77
Company Name Stock Ticker Symbol Market Type
Agenus Inc AGEN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.19 -6.33% 2.81 17:00:00
Open Price Low Price High Price Close Price Prev Close
2.96 2.77 2.97 2.81 3.00
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
8,736 2,461,283 $ 2.87 $ 7,071,850 - 1.25 - 3.62
Last Trade Time Type Quantity Stock Price Currency
16:59:47 2 $ 2.90 USD

Period:

Draw Mode:

Agenus Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 856.52M 304.81M 289.44M $ 295.66M $ 1.69M -0.21 -3.60
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 34.40k 2.80%

more financials information »

Agenus News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical AGEN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.253.312.7953.033,749,055-0.44-13.54%
1 Month2.453.372.012.755,485,2440.3614.69%
3 Months2.743.371.952.554,889,2130.072.55%
6 Months1.463.371.252.424,926,9691.3592.47%
1 Year3.323.621.252.524,631,793-0.51-15.36%
3 Years4.076.791.253.433,619,886-1.26-30.96%
5 Years3.946.791.253.372,709,665-1.13-28.68%

Agenus Description

Agenus Inc is an American biotechnology company. Its main target is immuno-oncology treatments. The company's portfolio consists of therapeutic antibodies and vaccines to treat immuno-oncology illnesses: cancers, shingles, malaria, glioblastoma, and others. Agenus treatments aim, by combining multiple antibody platforms, to stimulate the immune system to recognize and fight cancer cells. The company has been cooperating with companies like Incyte, Merck Sharpe & Dohme, and Recepta Biopharma to achieve over a dozen antibody programs. Some of its products include Prophage, AutoSynVax, QS-21 Stimulon, and others.